- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04539392
Avaliação da Sexualidade do Casal Infértil (INFEXO)
Avaliação da Sexualidade do Casal Infértil: Estudo de Coorte Prospectivo
The study hypothesis is that infertile couples experience an impact of their sexuality impacted during the diagnostic process carried out as part of the medically assisted procreation assessment, and also by the announcement of the possible cause of the couple's infertility. It is also conceivable that a disorder of the couple's sexuality forms the origin of, or is a contributor to, infertility.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
-
Nîmes, França
- CHU de Nimes
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
80 heterosexual infertile couples (according to the WHO definition) followed at the Nîmes University Hospital in the Urology / Gynecology departments.
Descrição
Inclusion Criteria:
- Couple in which each of the two partners has signed the consent form which is presented separately and independently of their partner.
- The patient must be a member or beneficiary of a health insurance plan
- Heterosexual infertile couple (according to the WHO definition) monitored at the Nîmes University Hospital in the urology / gynecology departments.
Adult patient (≥18 years old) and under 43 years old for women, 60 years old for men
Exclusion Criteria:
- The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
- One member of the couple refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient without good level of written and spoken French
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Casal infértil
|
Panel of questionnaires assessing sexuality, relationship satisfaction, and body image |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sexuality of the female of the couple
Prazo: 2 weeks after inclusion (start of MAP)
|
Female sexual function index: The total score is between 2 and 36 with sexual dysfunction indicated for scores below 26.55 |
2 weeks after inclusion (start of MAP)
|
|
Sexuality of the female of the couple
Prazo: 1 month after ovarian ponction (end of MAP)
|
Female sexual function index: The total score is between 2 and 36 with sexual dysfunction indicated for scores below 26.55 |
1 month after ovarian ponction (end of MAP)
|
|
Sexuality of the male of the couple
Prazo: 2 weeks after inclusion (start of MAP)
|
Male Sexual Health Questionnaire |
2 weeks after inclusion (start of MAP)
|
|
Sexuality of the male of the couple
Prazo: 1 month after ovarian ponction (end of MAP)
|
Male Sexual Health Questionnaire |
1 month after ovarian ponction (end of MAP)
|
|
Ejactulation of the male of the couple
Prazo: 2 weeks after inclusion (start of MAP)
|
Premature Ejaculation Profile |
2 weeks after inclusion (start of MAP)
|
|
Ejactulation of the male of the couple
Prazo: 1 month after ovarian ponction (end of MAP)
|
Premature Ejaculation Profile |
1 month after ovarian ponction (end of MAP)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sexuality of the female of the couple
Prazo: 1 month after ovarian ponction (end of MAP)
|
Female sexual function index: The total score is between 2 and 36 with sexual dysfunction indicated for scores below 26.55 |
1 month after ovarian ponction (end of MAP)
|
|
Sexuality of the male of the couple
Prazo: 1 month after ovarian ponction (end of MAP)
|
Male Sexual Health Questionnaire |
1 month after ovarian ponction (end of MAP)
|
|
Body satisfaction and global self-perception of both members of the couple
Prazo: 2 weeks after inclusion (start of MAP)
|
Questionnaire de satisfaction corporelle et de perception globale de soi (QSCPGS): total score ranges from -100 to +100. |
2 weeks after inclusion (start of MAP)
|
|
Body satisfaction and global self-perception of both members of the couple
Prazo: 1 month after ovarian ponction (end of MAP)
|
Questionnaire de satisfaction corporelle et de perception globale de soi (QSCPGS): total score ranges from -100 to +100. |
1 month after ovarian ponction (end of MAP)
|
|
Relationship satisfaction of both members of the couple
Prazo: 2 weeks after inclusion (start of MAP)
|
Dyadic Adjustment Scale-16 Distress if score less than 92 and without distress if the score is higher than 107 |
2 weeks after inclusion (start of MAP)
|
|
Relationship satisfaction of both members of the couple
Prazo: 1 month after ovarian ponction (end of MAP)
|
Dyadic Adjustment Scale-16 Distress if score less than 92 and without distress if the score is higher than 107 |
1 month after ovarian ponction (end of MAP)
|
|
Self-esteem of both members of the couple
Prazo: 2 weeks after inclusion (start of MAP)
|
Rosenberg self-esteem scale: The score is between 10 and 40. A score below 25 indicates very low self-esteem. A score between 25 and 31 indicates low self-esteem. A score between 31 and 34 indicates average self-esteem. A score between 34 and 39 indicates strong self-esteem. A score above 39 indicates very high self-esteem. |
2 weeks after inclusion (start of MAP)
|
|
Self-esteem of both members of the couple
Prazo: 1 month after ovarian ponction (end of MAP)
|
Rosenberg self-esteem scale: The score is between 10 and 40. A score below 25 indicates very low self-esteem. A score between 25 and 31 indicates low self-esteem. A score between 31 and 34 indicates average self-esteem. A score between 34 and 39 indicates strong self-esteem. A score above 39 indicates very high self-esteem. |
1 month after ovarian ponction (end of MAP)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Stéphanie Huberlant, CHU Nimes
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NIMAO/2019-2/SH-01
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .